NeoGenomics (NASDAQ: NEO) reported Q1 EPS of $0.03, $0.10 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $59.7 million versus the consensus estimate of $57 million.

GUIDANCE:

NeoGenomics sees FY2016 EPS of $0.08-$0.13, versus the consensus of ($0.22). NeoGenomics sees FY2016 revenue of $242-252 million, versus the consensus of $244.5 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.